International Journal of Clinical Research

Objective: Study on the treatment of acute cerebral infarction with the combination of butylphthalein soft capsules and edaravone. Methods: Selecting 100 patients with acute cerebral infarction admitted to our hospital from January 2023 to January 2024 as the research subjects, they were randomly divided into a control group (50 cases, treated with butylphthalein soft capsules) and an observation group (50 cases, treated with edaravone in addition to the control group). The clinical treatment effects of the two groups, such as the neurological function (NIHSS) score, quality of life (physiological function, psychological function, motor function) score, daily living ability (ADL) score, and serum neuron specific enolase, superoxide dismutase, and nitric oxide concentration, were compared and evaluated. Results: The neurological function of the observation group patients was significantly lower than that of the control group (P<0.05). The physiological, psychological, and motor function scores of the observation group patients were higher than those of the control group (P<0.05). The daily living ability score of the observation group patients was higher than that of the control group (P<0.05). The serum concentrations of neuron specific enolase, superoxide dismutase, and nitric oxide in the observation group were higher than those in the control group (P<0.05). Conclusion: The combination of ibuprofen soft capsules and edaravone can achieve significant results in the treatment of acute cerebral infarction patients, and can significantly improve their neurological function. Improve the quality of life and daily living abilities. It has high application value and is worth promoting and applying in clinical work.

Butylphthalide soft capsules; Edaravone; Acute cerebral infarction; Neurological function